

MAR 05 2002

TECH CENTER 1600/2900






SHEET 1 OF 1



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b> (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. <b>EPI-00671b</b>	SERIAL NO. <b>09/543,679</b>
	APPLICANT <b>Jonathan W. Nyce</b>	
	FILING DATE <b>April 4, 2000</b>	GROUP <b>1635</b>

[illegible]

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES		NO										
JL		9	6	4	0	1	6	2	12/19/96	WO	A61K	31/70		
		9	3	1	0	8	2	0	06/10/93	WO	A61K	48/00		
		9	8	1	1	2	1	1	03/19/98	WO	C12N	15/11		
		9	4	0	2	6	0	5	02/03/94	WO	C12N	15/12		
		9	8	2	3	2	9	4	06/04/98	WO	A61K	48/00		
		9	6	4	0	2	6	6	12/19/96	WO	A61K	48/00		
		9	3	1	2	7	5	6	07/08/93	WO	A61K			
		9	9	6	0	1	6	6	11/25/99	WO	C12Q	1/68		
		0	0	0	9	5	2	5	02/24/00	WO	C07H			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Rahman, M. Sayeedur, et al., "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenosine in vivo and in vitro", Mutation Research, vol. 377, no. 2, 1997, pages 263-268
	Loakes, D. et al., "5-Nitroindole as an universal base analogue", Nucleic Acids Research, vol. 22, no. 20, 1994, pages 4039-4043
	Ohtsuka, E. et al., "An alternative approach to deoxypolynucleotides as hybridization probes by insertion of deoxynosine at ambiguous codon positions", Journal of Biological Chemistry, vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605-2608
	Nichols, R. et al., "A universal nucleoside for use at ambiguous sites in DNA primers", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492-493
	Metzger W. James et al., "Oligonucleotide therapy of allergic asthma", Journal of Allergy and Clinical Immunology, vol. 104, no. 2 part 1, August 1999 (1999-08), pages 260-266

EXAMINER <i>Cheryl E. Ford</i>	DATE CONSIDERED <i>2-9-04</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	Not yet assigned
				<b>Filing Date</b>	herewith
				<b>First Named Inventor</b>	Jonathan W. Nyce
				<b>Group Art Unit</b>	not yet assigned
				<b>Examiner Name</b>	not yet assigned
<b>Sheet</b>		<b>of</b>	4	<b>Attorney Docket Number</b>	EPI-067191

[illegible][illegible]

Examiner Signature	<i>Chet H. Galt, Jr.</i>	Date Considered	2-9-04
-----------------------	--------------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box.



PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	Not yet assigned
Filing Date	herewith
First Named Inventor	Jonathan W. Nyce
Group Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	EPI-067191

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
JW		Stull, R.A. et al., "Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices", Nucleic Acids Research, 20(13): 3501-3508 (1992).	
		Monia, B.P. et al., "Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides", J. Biol. Chem., Vol. 267 No. 28, Issue of October 5, 1992-19962 (1992).	
		Pasternak, Gavril W., "Molecular Neuropharmacology", The Scientist, 10(8):14 (1996).	
		Research Program - Antisense Technology, Novopharm Biotech - Research Program - Antisense Web Page, <a href="http://www.novopharmbiotech.ca/asense.htm">http://www.novopharmbiotech.ca/asense.htm</a> .	
		Akhtar, S. et al., "In vivo studies with antisense oligonucleotides", Trends in Pharmacological Sciences, Current Techniques, 18:12-18, (1997).	
		Nyce, J.W., "Antisense oligonucleotides as emerging drugs", Emerging Drugs, 3:365-375, (1998).	
		Nyce, J.W., "Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases", Exp. Opin. Invest. Drugs 6(9): 1149-1156 (1997).	
		Nyce, J.W. et al., "DNA Antisense Therapy for Asthma in an Animal Model", Nature, 385(20): 721-725, (1997).	
		Webb, A. et al., "BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma", Lancet, 349(9059): 1137-41, (1997).	
		Yazaki, T. et al., "Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothioate Oligodeoxynucleotide", Molecular Pharmacol., 50(2): 236-242, (1996).	
JW		Farmer, S.G. et al., "Adenosine Receptor-mediated Contraction and Relaxation of Guinea-pig Isolated Tracheal Smooth Muscle: Effects of Adenosine Antagonists", Br. J. Pharmacol., 95: 371-378 (1988).	
		Marquardt, D.L. et al., "Aminophylline Exposure Alters Mouse Bone Marrow-derived Mast Cell Adenosine Responsiveness", J. Allergy Clin Immunol. 78: 462-469, (1986).	

Examiner  
Signature

*Jonathan W. Nyce*

Date  
Considered

*2-9-04*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DISCLOSURE  
BY APPLICANT**

(meets as necessary)

of 4

**Complete if Known**

Application Number	Not yet assigned
Filing Date	herewith
First Named Inventor	Jonathan W. Nvce
Group Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	EPI-067191

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T2

Simpson, R. U. et al, "Antisense oligonucleotide targeting against protein kinase C beta and C beta II block 1,25 -(OH)- 2D3- induced differentiation", J. Biol. Chem. 273(31):19587-19591 (1998).

Chen, CC et al, "Protein kinase Ceta mediates LPS-induced nitric oxide synthesis expression", J. Biol. Chem. 273(31): 19424-19430 (1998).

Glukhov, A. I., et al., "Inhibition of telomerase activity of melanoma cells in vitro by antisense oligodeoxynucleotides", Biochem. Biophys. Res. Commun. 248(2):368-371 (1998).

Banasiak, K. J. and Haddard G. G., "Hypoxia-induced apoptosis: effect of hypoxia severity and role of p53 in neuronal cell death (Antisense to p53)", Brain Res. 797(2): 295-304 (1998).

Lehenkaru P et al, "Carbonic anhydrase II plays a major role in osteoclast differentiation (antisense to carbonic anhydrase II)", Exp Cell Res 242(1):128-137 (1998).

Dooley NP et al, "Apoptosis is induced in glioma cells by antisense oligonucleotide to protein kinase C alpha", Neuroreport 9(8):1727-1733 (1998).

Kondo S et al, "Antisense telomerase treatment: induction of distinct pathways, apoptosis and differentiation", FASEB J. 129100:801-811 (1998).

Alahari SK et al, "Novel chemically modified oligonucleotide provide potent inhibition of p-glycoprotein (an ATPase that serves as a drug efflux pump)", J. Pharmacol. Exp. Therapeut. 286(1): 419-428 (1998).

Wu Pong, S. "Oligonucleotides: Opportunities for Drug Therapy and Research," Pharmaceutical Technology, Vol. 18: 102-114.

Miller et al. "Gene Transfer and Antisense Nucleic Acid Techniques," Parasitology Today, Vol. 10, No. 3: 92-97.

Stull et al. "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Pharmaceutical Research, Vol. 12, No. 4: 465-483.

Examiner  
Signature

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Order Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/088 (10-96)

Substitute for form 1449B/PT:

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

### Complete if Known

Application Number	Not yet assigned
Filing Date	herewith
First Named Inventor	Jonathan W. Nvce
Group Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	EPI-067191

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
-----------------------------------	--------------------------	---	----------------

J. MILLIGAN et al.; *Current Concepts in Antisense Drug Design*. J. Med. Chem. 36(14): 1923-1937 (1993).

S. ALI et al.; *Adenosine-induced bronchoconstriction in an allergic rabbit model: antagonism by theophylline aerosol*. Agents Actions 37:165-167 (1992).

S. ALI et al.; *Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol*. Agents Actions 37:168-170 (1992).

S. ALI et al.; *Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A<sub>1</sub> Receptor*. J. Pharmacol. Exp. Therapeu. 268:1328-1334 (1994).

S. ALI et al.; *Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model*. Am. J. Physiol. 266:L271-277 (1994).

D.R. SIBLEY, et al; *Transfected Mammalian Cell Lines Expressing the A1 Adenosine Receptor*  
NTIS Field/Group Codes: 57F, 57B, 57Q 90D (5 June 1991).

Dennis J. U., et al, "Human melanoma metastases is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C alpha", Cancer Lett. 128(1): 65-70 (1998).

Haeckel C., et al, "Antisense oligonucleotide inhibit urokinase", Int. J. Cancer 77(1): 153-160 (1998).

Kobayashi S. et al, "Transcription factor NF-E2 is essential for the polyploidization of Meg-J", Biochem. Biophys. Res. Commun. 247(1): 65-69 (1998).

Examiner  
Signature

Date  
Considered

2-9-04

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.